Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas - Test2 - elhamkhani - TriplyDB

Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas

Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas

http://www.wikidata.org/entity/Q35984566

about

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells.Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls.Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis.Wild-type BRCA1, but not mutated BRCA1, regulates the expression of the nuclear form of beta-catenin Novel therapeutic strategies in the treatment of triple-negative breast cancer.Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.Molecular insights on basal-like breast cancer.The multicellular tumor spheroid model for high-throughput cancer drug discovery.Characteristics of triple-negative breast cancer Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer.Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer.Laminin 332 expression in breast carcinoma Triple negative breast cancer - our experience and review Expression of CCL2 is significantly different in five breast cancer genotypes and predicts patient outcome.Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors.The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide Biomarkers for Basal-like Breast Cancer.Calretinin expression in high-grade invasive ductal carcinoma of the breast is associated with basal-like subtype and unfavorable prognosis.Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis.Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).Dysregulation of the BRCA1/long non-coding RNA NEAT1 signaling axis contributes to breast tumorigenesis.Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.Basal phenotype breast cancer: implications for treatment and prognosis.BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature.Understanding the biology of triple-negative breast cancer.Down-regulation of pseudogene Vimentin 2p is associated with poor outcome in de novo acute myeloid leukemia.Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort Characteristics of basal cytokeratin expression in breast cancer.A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard.Triple-Negative Breast Cancer: A Comprehensive Study of Clinical, Histomorphological, and Immunohistochemical Features in Indian Patients.Targeting EGFR in Triple Negative Breast Cancer.Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients.c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.A Phase II trial of Zoladex combined with CEF chemotherapy as neoadjuvant therapy in premenopausal women with hormone-responsive, operable breast cancer.Pathology of hereditary breast cancer.Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression.

P2860

Q24626194-9C28BA0A-2A65-4607-9FDE-9581E878C8FF Q30494216-EDAE2FB3-8DFA-49B1-9F30-F3AE093258A4 Q33557794-193A33F3-FA87-4F83-BBE7-C27C244ED291 Q33751806-4ED90F7B-FA8A-47D3-97A2-D56F436B7DBE Q33839776-82715450-581B-4D7E-9C6A-DC669AE186B9 Q33887682-409C5463-CE3A-4C81-B3EB-69FF9E934755 Q34081324-730C6707-F274-4E49-966C-1576DFCBB5E4 Q34123314-796C5D9A-DC77-48F2-9B73-115D355216C3 Q34334386-13A90D01-6031-4D89-8036-106A0FE0028F Q34479003-9A63830C-2D7F-46A6-B681-F271DA5820D7 Q34556770-62DFFE02-CB2E-482F-A2EF-22B072A0D05C Q35114444-71949883-9419-410D-8CE1-1956D5881282 Q35825928-8DEF4D06-5032-4C9C-BE70-95B488C400ED Q36024205-D6CC382C-DBD5-4D0E-9E75-B13BBB4A274D Q36317635-DAB7A227-7562-4B9C-A337-48D956E4C39C Q36473360-4439847F-38EB-4164-AAC0-D2C0B68B9D8A Q36580632-1AFE39DA-3C76-4AB2-9F94-A965927D69DD Q36640848-F2F83B10-D019-4B72-A5EB-11F3EDDFBA56 Q37328394-633EF1CA-1C85-434F-A2C4-1805B774A96D Q37338128-BE330F29-D421-47C9-AB26-415FD3FFE293 Q37364696-65DEB8D0-D94A-48BC-BD8E-931D14EB9B15 Q37565213-CD82750C-1008-492B-B0CE-CE0321552CBF Q37662194-35BF0E8C-7DA6-4174-92F9-C257DDD3E597 Q37687380-EC011C52-EB78-4260-9DE3-994808227FE2 Q37706346-324774FF-520B-492C-BF62-9B78EB49C124 Q37853555-939AB898-6968-4DA3-8EC5-261730B8BB71 Q37958686-FFC531A9-9CA9-4092-A6E8-0F225AFAA0B1 Q37967029-C5FABC20-CB93-4EB7-812C-41FE0B55311E Q38046574-57FD411E-E45F-4464-913B-AE8FBC38A723 Q40371904-B7817065-D41F-4BCF-87EE-F4745D81989E Q41130064-7F56B84F-386D-4325-8DB3-E09246548D4F Q42437202-F0D12077-DE09-4BB7-8026-A74DD4021BC8 Q42438922-3083107E-993D-488B-8A03-1A87189F8301 Q42498742-FF57D322-44F4-4289-B196-23C69D6966F8 Q42766317-C68AE6CF-F0AC-4FE7-BEA8-42FB46D6AD96 Q44234056-6689484C-9C0D-4215-90EF-5C050D5469A4 Q52633557-4E1DB3A9-1336-4FF1-974F-D54622AEAD76 Q54607080-D8BE5551-F1C2-4F81-9E26-F788780BBDC3 Q55110010-E5E3EB13-C059-47C6-BCC9-AF159E054E2A Q55687390-1F7CE9B7-9E13-4229-8EB4-621F6BC115E1

P2860

Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas

http://www.wikidata.org/entity/Q35984566

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Vimentin and laminin expressio ...... 1-associated breast carcinomas

@ast

Vimentin and laminin expressio ...... 1-associated breast carcinomas

@en

type

label

Vimentin and laminin expressio ...... 1-associated breast carcinomas

@ast

Vimentin and laminin expressio ...... 1-associated breast carcinomas

@en

prefLabel

Vimentin and laminin expressio ...... 1-associated breast carcinomas

@ast

Vimentin and laminin expressio ...... 1-associated breast carcinomas

@en

P1433

Q35984566-43771335-5802-4CD5-9FA7-323A787FDA18

P1476

Q35984566-6052B8B8-60AA-4BAE-AAD1-90D0C308B3FD

P2093

Q35984566-0DB05B91-1361-4D15-9516-9B18CAE881EE

Q35984566-713A9801-B24F-4241-8732-A2628CBF26E2

Q35984566-71C080C2-5116-45E4-99B1-13B4099192A6

Q35984566-A8CC182C-4605-4EDF-ADA9-B40C228EB37A

Q35984566-C8919081-F176-4C0B-AAEA-3F58567B690A

P2860

Q35984566-07E0122C-1B25-42D9-B681-093944ABE11B

Q35984566-0B7B3F56-1A39-4B94-82D7-BFFE8AE74DDF

Q35984566-0D7EC6DE-434D-4C60-A86C-89947F54F1BD

Q35984566-11AB7723-F4C9-4339-98C5-6E3AD68AA201

Q35984566-123867A8-4801-4CE9-8A46-1138830A148D

Q35984566-12BBBBAB-0078-41D5-8337-B4288A60CAB1

Q35984566-14BF12E8-5A5C-43CE-AA48-92750C7144F1

Q35984566-14FC4711-1248-4DC5-B7CA-B14900F8443F

Q35984566-15032BEC-7F8C-44E4-A04D-B2CD39664636

Q35984566-248E8A02-AFD9-4DCD-B06E-73BAB4E12DE9

P304

Q35984566-D048CD26-8DFD-4447-BF51-3779202E0CF3

P31

Q35984566-E2F8A349-5D41-4D0B-80A7-E62F9D09DB2C

P356

Q35984566-F7E4CA12-F758-4C15-AD2A-52C4EEC141AD

P407

Q35984566-9C9BD0F4-D7BC-4B66-8F39-318011A79B5E

P433

Q35984566-5D1CDD69-49C8-4D3A-A355-55EAEEAAF82D

P478

Q35984566-B34954B8-26DE-4B93-9595-0D3F83E2DF21

P50

Q35984566-712C7FAE-CD18-438E-A6A8-9B1144D6971B

Q35984566-CDCD236F-AA85-4134-AEE9-A9E4B67A3AB1

Q35984566-DFDD80F6-FE92-4BA6-A5C4-AEF49E442FD8

P577

Q35984566-1ED49322-BB6D-48A2-B418-66EC3D721215

P5875

Q35984566-EA5C1A2E-549A-4695-B04D-827412429964

P698

Q35984566-69EE90E7-C356-4567-93EA-2E0D4FD3AD2A

P932

Q35984566-7F45167D-2564-4D9A-8BD6-2D652418976A

P356

JCP.2006.042143

P1433

Journal of Clinical Pathology

P1476

Vimentin and laminin expressio ...... 1-associated breast carcinomas

@en

P2093

David Sarrió

http://www.w3.org/2001/XMLSchema#string

Francisco Calero

http://www.w3.org/2001/XMLSchema#string

Javier Benítez

http://www.w3.org/2001/XMLSchema#string

José Palacios

http://www.w3.org/2001/XMLSchema#string

Socorro María Rodríguez-Pinilla

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome

Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer

Laminin isoform expression in breast tumors.

Myoepithelial cells: good fences make good neighbors

Gene expression profiling predicts clinical outcome of breast cancer

Molecular portraits of human breast tumours

Repeated observation of breast tumor subtypes in independent gene expression data sets

Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer

Genes that mediate breast cancer metastasis to lung

Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells.

P304

1006-1012

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JCP.2006.042143

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

Gema Moreno-Bueno

David Hardisson

Emiliano Honrado

P577

2006-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6691568

http://www.w3.org/2001/XMLSchema#string

P698

17105822

http://www.w3.org/2001/XMLSchema#string

P932

1972443

http://www.w3.org/2001/XMLSchema#string